chr7-124870928-G-A

Variant summary

Our verdict is Uncertain significance. The variant received 4 ACMG points: 4P and 0B. PM1PP3_Moderate

The NM_015450.3(POT1):​c.238C>T​(p.Arg80Cys) variant causes a missense change. The variant allele was found at a frequency of 0.0000106 in 1,606,290 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R80H) has been classified as Uncertain significance.

Frequency

Genomes: 𝑓 0.000013 ( 0 hom., cov: 33)
Exomes 𝑓: 0.000010 ( 0 hom. )

Consequence

POT1
NM_015450.3 missense

Scores

6
8
5

Clinical Significance

Uncertain significance criteria provided, multiple submitters, no conflicts U:3

Conservation

PhyloP100: 3.98

Publications

2 publications found
Variant links:
Genes affected
POT1 (HGNC:17284): (protection of telomeres 1) This gene is a member of the telombin family and encodes a nuclear protein involved in telomere maintenance. Specifically, this protein functions as a member of a multi-protein complex that binds to the TTAGGG repeats of telomeres, regulating telomere length and protecting chromosome ends from illegitimate recombination, catastrophic chromosome instability, and abnormal chromosome segregation. Increased transcriptional expression of this gene is associated with stomach carcinogenesis and its progression. Alternatively spliced transcript variants have been described. [provided by RefSeq, Jul 2008]
POT1 Gene-Disease associations (from GenCC):
  • pulmonary fibrosis and/or bone marrow failure syndrome, telomere-related, 8
    Inheritance: AD Classification: STRONG, LIMITED Submitted by: Ambry Genetics, Labcorp Genetics (formerly Invitae)
  • tumor predisposition syndrome 3
    Inheritance: AD Classification: MODERATE Submitted by: Ambry Genetics
  • glioma susceptibility 9
    Inheritance: AD Classification: LIMITED Submitted by: Ambry Genetics
  • thyroid gland carcinoma
    Inheritance: AD Classification: LIMITED Submitted by: Ambry Genetics
  • cerebroretinal microangiopathy with calcifications and cysts 3
    Inheritance: AR Classification: LIMITED Submitted by: G2P, Ambry Genetics

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Uncertain_significance. The variant received 4 ACMG points.

PM1
In a hotspot region, there are 2 aminoacids with missense pathogenic changes in the window of +-8 aminoacids around while only 0 benign, 16 uncertain in NM_015450.3
PP3
MetaRNN computational evidence supports a deleterious effect, 0.859

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
POT1NM_015450.3 linkc.238C>T p.Arg80Cys missense_variant Exon 7 of 19 ENST00000357628.8 NP_056265.2 Q9NUX5-1A0A024R739

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
POT1ENST00000357628.8 linkc.238C>T p.Arg80Cys missense_variant Exon 7 of 19 2 NM_015450.3 ENSP00000350249.3 Q9NUX5-1

Frequencies

GnomAD3 genomes
AF:
0.0000132
AC:
2
AN:
152048
Hom.:
0
Cov.:
33
show subpopulations
Gnomad AFR
AF:
0.00
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.000192
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.0000147
Gnomad OTH
AF:
0.00
GnomAD2 exomes
AF:
0.0000203
AC:
5
AN:
246590
AF XY:
0.0000300
show subpopulations
Gnomad AFR exome
AF:
0.00
Gnomad AMR exome
AF:
0.0000899
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.0000178
Gnomad OTH exome
AF:
0.00
GnomAD4 exome
AF:
0.0000103
AC:
15
AN:
1454242
Hom.:
0
Cov.:
29
AF XY:
0.00000829
AC XY:
6
AN XY:
723438
show subpopulations
African (AFR)
AF:
0.00
AC:
0
AN:
33166
American (AMR)
AF:
0.0000455
AC:
2
AN:
43950
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
25864
East Asian (EAS)
AF:
0.0000254
AC:
1
AN:
39342
South Asian (SAS)
AF:
0.00
AC:
0
AN:
85000
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
53120
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
5700
European-Non Finnish (NFE)
AF:
0.0000108
AC:
12
AN:
1108102
Other (OTH)
AF:
0.00
AC:
0
AN:
59998
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.415
Heterozygous variant carriers
0
1
2
2
3
4
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.0000132
AC:
2
AN:
152048
Hom.:
0
Cov.:
33
AF XY:
0.00
AC XY:
0
AN XY:
74262
show subpopulations
African (AFR)
AF:
0.00
AC:
0
AN:
41416
American (AMR)
AF:
0.00
AC:
0
AN:
15264
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
3472
East Asian (EAS)
AF:
0.000192
AC:
1
AN:
5200
South Asian (SAS)
AF:
0.00
AC:
0
AN:
4834
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
10600
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
316
European-Non Finnish (NFE)
AF:
0.0000147
AC:
1
AN:
67944
Other (OTH)
AF:
0.00
AC:
0
AN:
2090
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.500
Heterozygous variant carriers
0
0
1
1
2
2
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.0000434
Hom.:
0
Bravo
AF:
0.0000151
TwinsUK
AF:
0.000270
AC:
1
ALSPAC
AF:
0.00
AC:
0
ExAC
AF:
0.00000824
AC:
1

ClinVar

Significance: Uncertain significance
Submissions summary: Uncertain:3
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not provided Uncertain:1
Apr 19, 2022
GeneDx
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Observed in an individual with multiple primary melanoma (Muller 2018); This variant is associated with the following publications: (PMID: 28393830, 29523635) -

Tumor predisposition syndrome 3 Uncertain:1
Jan 14, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This sequence change replaces arginine, which is basic and polar, with cysteine, which is neutral and slightly polar, at codon 80 of the POT1 protein (p.Arg80Cys). This variant is present in population databases (rs778692211, gnomAD 0.009%). This missense change has been observed in individual(s) with melanoma (PMID: 29523635). ClinVar contains an entry for this variant (Variation ID: 541863). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is not expected to disrupt POT1 protein function with a negative predictive value of 80%. RNA analysis performed to evaluate the impact of this missense change on mRNA splicing indicates it does not significantly alter splicing (internal data). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -

Hereditary cancer-predisposing syndrome Uncertain:1
Feb 02, 2024
Ambry Genetics
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

The p.R80C variant (also known as c.238C>T), located in coding exon 3 of the POT1 gene, results from a C to T substitution at nucleotide position 238. The arginine at codon 80 is replaced by cysteine, an amino acid with highly dissimilar properties. This alteration was detected in an Austrian individual with multiple primary melanomas but was not present in the control cohort (M&uuml;ller C et al. G3 (Bethesda). 2018 05;8:1475-1480). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the available evidence, the clinical significance of this alteration remains unclear. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Uncertain
0.41
BayesDel_addAF
Uncertain
0.13
D
BayesDel_noAF
Pathogenic
0.15
CADD
Pathogenic
27
DANN
Uncertain
1.0
DEOGEN2
Pathogenic
0.91
D;D
Eigen
Uncertain
0.67
Eigen_PC
Pathogenic
0.68
FATHMM_MKL
Pathogenic
0.97
D
LIST_S2
Uncertain
0.89
D;.
M_CAP
Benign
0.040
D
MetaRNN
Pathogenic
0.86
D;D
MetaSVM
Benign
-0.62
T
MutationAssessor
Uncertain
2.0
M;.
PhyloP100
4.0
PrimateAI
Uncertain
0.65
T
PROVEAN
Pathogenic
-5.5
D;D
REVEL
Uncertain
0.42
Sift
Benign
0.071
T;T
Sift4G
Benign
0.088
T;.
Polyphen
0.99
D;.
Vest4
0.88
MutPred
0.71
Loss of MoRF binding (P = 0.0069);Loss of MoRF binding (P = 0.0069);
MVP
0.86
MPC
2.3
ClinPred
0.88
D
GERP RS
5.6
Varity_R
0.72
gMVP
0.91
Mutation Taster
=18/82
disease causing

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.23
Details are displayed if max score is > 0.2
DS_DL_spliceai
0.23
Position offset: -17

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs778692211; hg19: chr7-124510982; COSMIC: COSV62934564; COSMIC: COSV62934564; API